The control of lipid and glucose metabolism is closely linked. The nuclear receptors liver X receptor (LXR)␣ and LXR␤ have been implicated in gene expression linked to lipid homeostasis; however, their role in glucose metabolism is not clear. We demonstrate here that the synthetic LXR agonist GW3965 improves glucose tolerance in a murine model of diet-induced obesity and insulin resistance. Analysis of gene expression in LXR agonist-treated mice reveals coordinate regulation of genes involved in glucose metabolism in liver and adipose tissue. In the liver, activation of LXR led to the suppression of the gluconeogenic program including down-regulation of peroxisome proliferator-activated receptor ␥ coactivator-1␣ (PGC-1), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase expression. Inhibition of gluconeogenic genes was accompanied by an induction in expression of glucokinase, which promotes hepatic glucose utilization. In adipose tissue, activation of LXR led to the transcriptional induction of the insulin-sensitive glucose transporter, GLUT4. We show that the GLUT4 promoter is a direct transcriptional target for the LXR͞retinoid X receptor heterodimer and that the ability of LXR ligands to induce GLUT4 expression is abolished in LXR null cells and animals. Consistent with their effects on GLUT4 expression, LXR agonists promote glucose uptake in 3T3-L1 adipocytes in vitro. Thus, activation of LXR alters the expression of genes in liver and adipose tissue that collectively would be expected to limit hepatic glucose output and improve peripheral glucose uptake. These results outline a role for LXRs in the coordination of lipid and glucose metabolism. L iver X receptor (LXR)␣ and LXR␤ have emerged as important regulators of lipid and lipoprotein metabolism. The LXRs are activated by physiological concentrations of oxidized derivatives of cholesterol such as 22(R)-hydroxycholesterol, 27-hydroxycholesterol, and 24(S),25-epoxycholesterol (1-3). LXR␣ is expressed at particularly high levels in liver, adipose tissue, and macrophages, whereas LXR␤ is expressed ubiquitously. These ligand-activated transcription factors form obligate heterodimers with the retinoid X receptor (RXR) and regulate the expression of target genes containing LXR response elements (LXREs). All the LXREs identified thus far are DR-4 hormone response elements (direct repeat of the consensus AGGTCA separated by four nucleotides) (4).
L
iver X receptor (LXR)␣ and LXR␤ have emerged as important regulators of lipid and lipoprotein metabolism. The LXRs are activated by physiological concentrations of oxidized derivatives of cholesterol such as 22(R)-hydroxycholesterol, 27-hydroxycholesterol, and 24(S), 25-epoxycholesterol (1-3) . LXR␣ is expressed at particularly high levels in liver, adipose tissue, and macrophages, whereas LXR␤ is expressed ubiquitously. These ligand-activated transcription factors form obligate heterodimers with the retinoid X receptor (RXR) and regulate the expression of target genes containing LXR response elements (LXREs). All the LXREs identified thus far are DR-4 hormone response elements (direct repeat of the consensus AGGTCA separated by four nucleotides) (4) .
To date, more than a dozen LXR target genes have been identified (5) . In the liver, LXRs regulate expression of a number of proteins involved in cholesterol and fatty acid metabolism, including CYP7A and sterol regulatory binding element protein 1c (SREBP-1c) (6, 7) . In macrophages and other peripheral cells, LXRs have been implicated in the reverse cholesterol transport pathway. LXRs control the transcription of several genes involved in cellular cholesterol efflux including ATP-binding cassette (ABC)A1, ABCG1, and apolipoprotein E (8) (9) (10) (11) . LXRs also seem to influence lipoprotein metabolism through the control of modifying enzymes such as lipoprotein lipase, cholesteryl ester transfer protein, and phospholipid transfer protein (12) (13) (14) (15) (16) .
Here we outline a previously unrecognized role for LXRs in the control of glucose metabolism in liver and adipose tissue. We demonstrate that activation of LXR in the liver leads to the induction of glucokinase expression and to the down-regulation of peroxisome proliferator-activated receptor ␥ coactivator-1␣ (PGC-1) and genes involved in gluconeogenesis. We also show that the insulin-sensitive glucose transporter GLUT4 is a direct target for regulation by the LXR͞RXR heterodimer in adipose tissue. Finally, we demonstrate that a synthetic LXR agonist improves glucose tolerance in a model of diet-induced obesity and insulin resistance. These observations outline a role for the LXRs in the coordination of lipid and glucose metabolism and suggest that LXR agonists may have utility in the modulation of glucose homeostasis.
Materials and Methods
Reagents and Cell Culture. pCMX expression plasmids for LXR␣, LXR␤, and RXR␣ have been described (11) . GW3965 was kindly provided by Jon Collins and Timothy Willson (GlaxoSmithKline). T1317 was from Cayman Chemical (Ann Arbor, MI). Ligands were dissolved in ethanol or DMSO before use in cell culture. For gene-expression studies, 3T3-L1 cells were cultured in DMEM containing 10% FBS and differentiated into adipocytes by treatment with dexamethasone, methylisobutylxanthine, and 50 nM GW7845. Peritoneal macrophages were obtained from thioglycolate-injected mice as described (11) and cultured in DMEM containing 5% lipoprotein-deficient serum and receptor ligands for 24 h as indicated. For stable promoter studies, undifferentiated 3T3-L1 cells were infected with self-inactivating retroviruses carrying various truncations of the human GLUT4 promoter linked to a luciferase reporter. Stable clones were selected and induced to differentiate into mature adipocytes. On day 8 of differentiation, cells were incubated in serum-free medium supplemented with T1317 as indicated. Luciferase activity was measured 24 h later. Transient transfections of NIH 3T3 cells were performed as described (17) . All experiments were performed in triplicate.
RNA and DNA Analysis. Real-time quantitative PCR assays were performed by using an Applied Biosystems 7700 sequence detector. Total RNA was reverse-transcribed with random hexamers by using TaqMan reverse-transcription reagents kit (Applied Biosystems) according to manufacturer protocol. RNA expression was determined by Sybr green or TaqMan assays as described (18) . Statistical analysis of mRNA expression data were performed by using the Student's t test. Probe and primer sequences are available on request. For gel-shift assays, in vitro-translated RXR␣ and LXR␣ were generated from pCMX-RXR␣ and pCMX-hLXR␣ plasmids (19) by using the TNT quick-coupled transcription͞ translation system (Promega). Gel-shift assays were performed as described (20) by using in vitro-translated proteins and the following oligonucleotides (only one strand is shown): mGLUT4 LXRE, 5Ј-gatcctccgggttacttcggggcataca-3Ј; hGLUT4 LXRE, 5Ј-gatcccccgggttactttggggcattgc-3Ј; and GLUT4 mut, 5Ј-gatcctccggaatacttcggaacataca-3Ј.
Glucose Uptake. Glucose-uptake assays were performed in triplicate in differentiated 3T3-L1 adipocytes. Briefly, on day 6 postdifferentiation, 3T3-L1 cells were plated into 96-well Cytostar-T microplates (Amersham Pharmacia) at a density of 50,000 cells per well in 10% FBS-supplemented DMEM. On day 10, the medium was replaced with serum-free medium supplemented with T1317 as indicated. Twenty hours after compound addition, cells were washed twice with KRH buffer (125 mM NaCl͞5 mM KCl͞1.8 mM CaCl 2 ͞2.6 mM MgSO 4 ͞5 mM Hepes, pH 7.2) and incubated with FCS buffer (KRH buffer plus 2 mM sodium pyruvate͞2% BSA). After 1 h, PBS or insulin (as a control) was added to the cells and incubated for 15 min. In some wells, 20 M cytochalasin B was also added for background subtraction of nonspecific glucose uptake. Cells were incubated with glucose mixture [0.125 Ci per well 14 C-labeled deoxyglucose͞100 M deoxyglucose in PBS (1 Ci ϭ 37 GBq)] for 20 min at 37°C and quenched on ice. Cells were washed with ice-cold KRH buffer, and the radioactivity was quantitated.
Animals and Diets. For gene-expression studies, 10-week-old female C57BL͞6 mice were maintained on standard rodent chow and gavaged daily with GW3965 (20 mg͞kg per day) or vehicle (0.5% methylcellulose) for 3 days before being killed. LXR␣␤ Ϫ͞Ϫ mice on a mixed background and wild-type age-matched controls were maintained on standard chow and treated with vehicle or GW3965 (20 mg͞kg per day) for 3 days before being killed. All mice were killed during midlight cycle after a 12-h fast. For diet-induced obesity studies, C57BL͞6 mice were fed a high-fat diet for 3 months (Clinton͞Cybulsky rodent diet, 40% kcal from fat, devoid of cholesterol; Research Diets, New Brunswick, NJ). After 3 months, mice were treated for 1 week with vehicle or 20 mg͞kg per day GW3965 by gavage or supplementation in the chow as indicated. All mice received their final dose of GW3965 by gavage 2-8 h before glucosetolerance test and͞or being killed. Glucose-tolerance tests were performed by i.p. injection of glucose at 2 g͞kg body weight after 8 h of fasting. Studies were conducted in accordance with the Animal Research Committee of the University of California, Los Angeles.
Results
We investigated whether activation of LXRs altered the expression of genes involved in glucose metabolism. C57BL͞6 mice (nine animals per group) were treated for 3 days with either vehicle or 20 mg͞kg body weight of the synthetic LXR agonist GW3965 (21) . At the end of the treatment period, mice were fasted overnight, and total RNA was isolated. Gene expression was analyzed by real-time quantitative PCR assays. The levels of mRNA expression were determined for each animal individually, and the average expression for each group is presented in Fig. 1 . In the liver, treatment with GW3965 led to a strong induction of SREBP-1c and fatty acid synthase (FAS) mRNA, consistent with previous work (7). Moreover, LXR agonist treatment also altered expression of a number of genes linked to glucose metabolism. Treatment with GW3965 decreased expression of the transcriptional coactivator PGC-1, which was identified recently as a key regulator of gluconeogenesis (22) . Consistent with the decrease in PGC-1, expression of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase were also down-regulated by GW3965. In addition to these repressive effects, LXR agonist induced expression of glucokinase mRNA. The glucokinase gene is positively regulated by insulin, and its expression is an important determinant of hepatic glucose metabolism. In contrast, expression of the peroxisome proliferator-activated receptor ␣ target gene acyl-CoA oxidase was not altered by LXR ligand in these animals.
In adipose tissue, treatment with GW3965 led to the induction of SREBP-1c and ABCA1 expression, consistent with previous work (Fig. 1B) . In contrast to the effects observed in liver, expression of PGC-1 was not altered in white fat, indicating that the effects of LXR on this gene are tissue-specific. Interestingly, LXR agonist also stimulated expression of the insulin-sensitive glucose transporter GLUT4 in adipose tissue but had no effect on expression of GLUT1. In skeletal muscle, LXR ligand induced ABCA1 mRNA as expected (23) but did not alter GLUT4 expression (Fig. 1C) . We also examined the effect of LXR agonist on the expression of adipocyte signaling molecules known to modulate glucose metabolism and insulin sensitivity (Fig. 1D) . Activation of LXR led to a modest increase in expression of resistin and adiponectin but had no effect on expression of either leptin or tumor necrosis factor-␣.
We further examined the ability of this compound to regulate gene expression in mice carrying targeted disruptions in both the lxr␣ and lxr␤ genes. As shown in Fig. 2 , the ability of GW3965 to regulate hepatic expression of SREBP-1c, PGC-1, and PEPCK is lost in mice lacking LXRs. Glucokinase expression was also not induced by LXR agonists in livers of LXR null mice (data not shown). Similarly, white adipose tissue expression of ABCA1 and GLUT4 was not significantly altered by LXR agonist in LXR null mice. Together, these observations indicate that LXRs coordinately regulate expression of genes involved in glucose homeostasis in liver and adipose tissue.
The effects of LXR activation on hepatic gene expression are similar to the effects of insulin in this tissue. We therefore investigated whether expression of LXR␣ or LXR␤ was altered by fasting. As shown in Fig. 3 , expression of LXR␣ and LXR␤ was not different between fasted and fed animals. In contrast, SREBP-1c, FAS, and PEPCK gene expression was markedly regulated in these same animals (Fig. 3) . These observations suggest that although LXR is an important regulator of SREBP-1c expression, alteration of LXR mRNA expression is unlikely to play a significant role in the induction of SREBP-1c expression in response to the fed state.
We next investigated whether LXR agonists could regulate PGC-1 and GLUT4 expression in isolated cells. Treatment of primary human hepatocytes for 24 h with 1 M GW3965 strongly repressed expression of PGC-1 and induced expression of FAS, consistent with the in vivo effects (Fig. 4A) . Treatment of differentiated 3T3-L1 adipocytes with GW3965 led to a modest but significant increase in GLUT4 and ABCA1 expression (Fig. 4B) , also consistent with the results observed in vivo. To confirm the LXR-dependence of these effects, we isolated peritoneal macrophages from either wild-type or LXR null mice and cultured them in the presence of the oxysterol LXR ligand 22(R)-hydroxycholesterol, the synthetic LXR agonist T1317, and͞or the RXR-specific agonist LG268. In wild-type cells, GLUT4 expression was induced by both LXR agonists, and the combination of an LXR agonist and an RXR agonist had an additive effect (Fig. 4 C and D) . In contrast, the ability of these compounds to regulate GLUT4 expression was abolished in cells lacking LXRs (Fig. 4D) . Similar results were obtained when GW3965 was used in place of T1317 (data not shown). Thus, the ability of LXR agonists to regulate PGC-1 and GLUT4 expression is cell-autonomous and does not seem to require the production of systemic mediators.
We analyzed the GLUT4 promoter region from the mouse and human genes and identified a conserved DR-4 hormone response element (GLUT4 LXRE, Fig. 5A ). In the human, this sequence is located at position Ϫ463 bp relative to the transcriptional initiation site, and in the mouse it is located at position Ϫ420 bp. Electrophoretic mobility-shift assays using in vitro-translated proteins demonstrated that LXR␣͞RXR␣ heterodimers bound to an oligonucleotide spanning this site (Fig. 5B) . The specificity of the shifted complex was confirmed by competition with excess unlabeled mGLUT4 or hGLUT4 LXRE oligonucleotide. In contrast, an oligonucleotide carrying a mutation in the LXRE did not compete.
To determine whether this sequence was a functional LXRE, we tested the ability of LXR agonists to activate the human GLUT4 promoter. 3T3-L1 adipocytes carrying stably integrated human GLUT4 promoter-luciferase reporter constructs were cultured for 24 h in the presence of various concentrations of T1317. As shown in Fig. 5C , activity of the Ϫ1,183-bp construct was enhanced when cells were treated with T1317 in a dose-dependent manner. Deletion of sequences between Ϫ1,183 and Ϫ508 bp did not alter ligand responsiveness; however, deletion of the region between Ϫ508 and Ϫ417 bp, which contains the LXRE, abolished the response. We further tested the ability of LXRs to transactivate the GLUT4 promoter in transient transfection assays. The Ϫ1,183-bp promoter construct was cotransfected into NIH 3T3 cells along with expression vectors for LXR␣ and RXR␣. Expression of this construct was strongly stimulated by LXR͞RXR in a ligand-dependent manner (Fig. 5D) . Furthermore, LXR activation of the Ϫ1,183-bp GLUT4 promoter construct was reduced dramatically when a specific mutation was introduced into the Ϫ463-bp LXRE, suggesting that this is the primary element mediating induction by LXR. Taken together, the results of Fig. 5 indicate that the GLUT4 promoter is a direct target for regulation by LXR.
The ability of LXR to regulate GLUT4 expression suggested that LXR ligands might modulate glucose uptake in isolated adipocytes. To investigate this possibility, we performed glucose-uptake assays in differentiated 3T3-L1 adipocytes. As shown in Fig. 6A , treatment of the cells with T1317 significantly increased basal glucose uptake, consistent with previous work (24) . Furthermore, LXR agonist also increased insulin-stimulated glucose uptake in 3T3-L1 cells (Fig.  6B) . Parallel samples processed for RNA analysis confirmed increased expression of GLUT4 mRNA in these cells under assay conditions (Fig. 6C) . Ross et al. (24) reported that GLUT1 protein expression was increased by T1317 in 3T3-L1 cells; however, GLUT1 mRNA expression was not altered by LXR agonist in our study.
Finally, we investigated the ability of the synthetic LXR agonist GW3965 to influence glucose tolerance in a model of diet-induced obesity and insulin resistance. C57BL͞6 mice were maintained on a high-fat diet for 3 months. The obese mice (six animals per group) were treated for 1 week with either vehicle or 20 mg͞kg body weight GW3965. Mice were fasted overnight, glucose-tolerance tests were performed, and plasma lipid levels were determined. Fig. 7A demonstrates that treatment with the LXR agonist significantly improved glucose tolerance (P Ͻ 0.01 at 15, 30, and 60 min) in obese mice. In contrast, GW3965 had a minimal effect on the normal glucose tolerance of lean C57BL͞6 mice maintained on normal chow diet (Fig. 7B) . Fasting glucose and insulin levels were not different between treated and untreated groups (Table 1 , which is published as supporting information on the PNAS web site, www.pnas.org). There was also no statistically significant difference in free fatty acids or triglyceride levels. These results demonstrate that activation of the LXR signaling pathway modulates glucose as well as lipid homeostasis in vivo.
Discussion
The control of lipid and glucose metabolism are closely linked. In the fed state, insulin stimulates peripheral glucose uptake, suppresses hepatic glucose production, and stimulates de novo lipogenesis. Disorders of lipid metabolism can lead to the impairment of peripheral glucose utilization and the development of insulin resistance and type II diabetes. Here we present data to suggest that the nuclear receptors LXR␣ and LXR␤ play a role in the coordinated regulation of lipid and glucose metabolism. We have shown that activation of LXRs with synthetic agonist leads to the suppression of genes involved in gluconeogenesis and induction of hepatic glucokinase expression and insulin-sensitive glucose transporter GLUT4 in adipose tissue. Together, these effects would be expected to limit hepatic glucose production and promote peripheral glucose uptake. Consistent with this hypothesis, we have shown that LXR agonists promote glucose uptake in 3T3-L1 adipocytes and improve glucose tolerance in a model of diet-induced insulin resistance. Finally, we have shown that the GLUT4 promoter is a direct target for the LXR͞RXR heterodimer. These observations identify the LXR signaling pathway as a potential target for the pharmacologic modulation of glucose metabolism.
The effects of LXR activation on hepatic gene expression are remarkably similar to the effects of insulin in this tissue. A principal of GW3965 on glucose tolerance in lean C57BL͞6 mice. Lean C57BL͞6 mice were maintained on normal chow diet and treated as described above. * , P Ͻ 0.05; ** , P Ͻ 0.01. mechanism whereby insulin alters gene expression in this tissue is through transcriptional up-regulation of SREBP-1c (25) . Transgenic expression of SREBP-1c in liver induces the entire program of fatty acid synthesis (26) . Moreover, the fasting͞refeeding response is compromised in SREBP-1c null mice (27) . Recent studies have also shown that adenoviral expression of SREBP-1c in liver induces expression of glucokinase and represses the expression of gluconeogenic genes such as PEPCK and glucose-6-phosphatase (28) (29) (30) . Thus, many of the effects of insulin on both lipid and glucose metabolism may be mediated by SREBP-1c. The results presented here suggest that activation of LXR is also a mechanism for modulation of the gluconeogenic program. Because SREBP-1c is a direct target of LXR, it is possible that many of the effects of LXR agonists in liver are the result of increased expression of SREBP-1c. LXR ligands may mimic the effects of insulin in the liver, because they mimic the effects of insulin on SREBP-1c expression.
An important question, then, is whether LXRs are involved in the physiologic effects of insulin or whether endogenous LXR ligands signal through a parallel pathway. Others have reported that LXR␣ expression in the liver is induced by insulin (31) . By contrast, in our studies expression of LXR␣ and LXR␤ was not different between fasted and fed animals, even though SREBP-1c expression was strongly regulated in these same animals (Fig. 3) . LXR expression is clearly required for the optimal expression of SREBP-1c, because SREBP-1c expression is extremely low in LXR null animals (7). However, our data suggest that it is unlikely that modulation of LXR␣ or LXR␤ mRNA expression is the principal mechanism for regulation of SREBP-1c expression during fasting͞feeding.
The results presented here raise the possibility that aspects of the LXR signaling pathway may be amenable to pharmacologic manipulation in the context of insulin resistance. A critical question in this regard is whether the beneficial effects of LXR agonists on hepatic glucose metabolism can be separated from effects on SREBP-1c. If not, then suppression of gluconeogenesis would invariably be accompanied by induction of de novo lipogenesis. Accumulation of triglycerides in the liver would offset the beneficial effects on blood glucose levels. In fact, we have observed that treatment of ob͞ob or KKAy mice for 2 weeks with LXR ligand does not improve glucose tolerance but dramatically raises plasma triglyceride levels and leads to profound hepatic steatosis (data not shown). Thus, it is likely that LXR effects on glucose metabolism would need to be separated from SREBP-1c-dependent effects on lipogenesis before LXR agonists would be useful as antidiabetic agents. Additional work will be required to decipher the mechanism of LXR action on hepatic expression of genes such as PGC-1 and glucokinase. Another potential mechanism whereby LXR activity may impact hepatic glucose metabolism was reported recently by Stulnig et al. (32) , who showed that 11␤-hydroxysteroid dehydrogenase type 1 and PEPCK expression are reduced by LXR ligands.
In contrast to many of the effects of LXR agonists in the liver, induction of GLUT4 expression in adipose tissue seems to result from direct action of LXR on the GLUT4 promoter. Previous work has shown that adipose expression of GLUT4 is an important determinant of insulin sensitivity (33) . In diabetic rodents and humans, insulin resistance leads to suppression of GLUT4 expression in adipose tissue. Transgenic expression of GLUT4 in white fat improves glucose disposal and ameliorates insulin resistance in diabetic mice (34) . Conversely, selective elimination of GLUT4 expression in adipose tissue impairs insulin action in muscle and liver (35) . Thus, the development of tissue or gene-selective LXR modulators may allow adipose GLUT4 expression to be regulated independent of lipogenic genes such as SREBP-1c and FAS. More research will be required to determine whether such compounds might have utility as modulators of glucose disposal and insulin resistance in syndromes of obesity͞diabetes.
